Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

MLA

Berenson, J. R., et al. “Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events. Myeloma Aredia Study Group.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 16, no. 2, Feb. 1998, pp. 593–602. EBSCOhost, https://doi.org/10.1200/JCO.1998.16.2.593.

APA

Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., Blacklock, H., Bell, R., Simeone, J. F., Reitsma, D. J., Heffernan, M., Seaman, J., & Knight, R. D. (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 16(2), 593–602. https://doi.org/10.1200/JCO.1998.16.2.593

Chicago

Berenson, J R, A Lichtenstein, L Porter, M A Dimopoulos, R Bordoni, S George, A Lipton, et al. 1998. “Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events. Myeloma Aredia Study Group.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 16 (2): 593–602. doi:10.1200/JCO.1998.16.2.593.